TITLE:
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
Indinavir sulfate

SUMMARY:

      The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug
      combinations when given to HIV-infected patients who have never been treated with anti-HIV
      drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The
      other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.
    

DETAILED DESCRIPTION:

      100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan
      (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir
      (Lamivudine) + Crixivan (Indinavir).

      Patients will be treated for 48 weeks.
    

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Documented HIV infection.

          -  CD4 cell count of 200 - 700 cells/mm3.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

        AIDS defining condition within 1 month of study entry.

        Prior Medication:

        Excluded:

        Patients with any history of antiretroviral therapy treatment.
      
